Medical Library | Shanghai Specialty Care and Clinical Innovation Series
Shanghai Jiao Tong University-affiliated Ninth People's Hospital is a major center for oral and maxillofacial surgery, craniofacial reconstruction, plastic and reconstructive surgery, orbital disease, and thyroid eye disease. Its 2025–2026 progress connects targeted medicine, reconstructive and sequence-based surgery, scar biology, smart devices, medical robotics, and multidisciplinary care.
This Medical Library review summarizes three representative teams and directions based on the information provided. It also explains how CMCS can help international patients prepare records and communicate with oral and maxillofacial, reconstructive, and ophthalmic specialists in Shanghai.
1. Oral and Maxillofacial Surgery: Targeted Treatment and Sequence-Based Care for Vascular Malformations
Leads: Professor Wang Xudong, President of the hospital, with Professors Cai Ming and Zhu Min
Focus: Cleft lip and palate sequence treatment, vascular malformations, and craniofacial reconstruction.
Vascular malformations can affect appearance, swallowing, breathing, speech, vision, and psychological well-being. Treatment is often staged and may involve imaging, interventional therapy, medication, surgery, reconstruction, and long-term follow-up.
Key 2025–2026 milestones
- Targeted medicine: In February 2026, the first domestic clinical trial of a targeted medicine for vascular malformations was launched. The supplied information reports that lesions were reduced by more than half after 16 weeks of treatment.
- National infrastructure: The Pudong campus of the National Center for Stomatology opened in March 2026.
The reported response is clinically encouraging, but families should confirm the exact drug, target, disease subtype, study design, imaging method, and whether the treatment is approved or available only in a clinical trial. Vascular malformations are not one disease. Venous, lymphatic, arteriovenous, and mixed malformations may require different strategies.
For cleft lip and palate, “sequence treatment” means that care is planned over time rather than limited to one operation. It may include feeding support, primary repair, speech assessment, orthodontics, hearing care, secondary surgery, and psychosocial support.
Our Oral and Maxillofacial Surgery at Shanghai Ninth People's Hospital guide provides related background for international patients.
Clinical profile: A national-level craniofacial program combining targeted medicine, staged surgery, and a specialized oral and maxillofacial center.
2. Reconstructive Surgery: From Keloid Standards to Smart Scar Devices
Leads: Professors Liu Wei, Wu Xiaoli, and Lin Xiaoxi
Focus: Pathological scars, hemangiomas and vascular malformations, and tissue engineering.
Key 2025–2026 milestones
- Keloid radiotherapy: The first reported domestic and international expert consensus on standardized adjuvant radiotherapy for keloids, the 2026 edition, was released.
- CEBPA small activating RNA: A preclinical approach using a small activating RNA directed at CEBPA was reported in Dermatologic Therapy in April 2026.
- Personalized silicone therapy: Registration of an intelligent silicone liner for personalized scar treatment was reported in August 2026 through ChiCTR.
Keloid management often requires combined treatment. Depending on the scar, options may include surgical removal, pressure therapy, silicone, corticosteroid or other injections, laser treatment, radiotherapy, and long-term prevention of recurrence. No single method works for every patient.
Adjuvant radiotherapy after keloid surgery can reduce recurrence in selected cases, but the timing, field, dose, age, pregnancy status, body site, and previous treatment must be reviewed carefully. Patients should ask about wound healing, pigmentation, recurrence risk, radiation exposure, and alternatives.
The CEBPA small activating RNA project remains a preclinical research direction. A laboratory mechanism should not be confused with an approved scar medicine. The intelligent silicone liner is also a registered development program, not proof that the device will provide the same benefit for every scar type.
Clinical profile: A reconstructive program moving from expert consensus and standardized radiotherapy to molecular research and personalized scar-management devices.
3. Ophthalmology and Orbital Disease: Targeted Therapy, Insurance Access, and Surgical Robotics
Leads: Academician Fan Xianqun and Professor Zhou Huifang
Focus: Thyroid eye disease, orbital fractures, and orbital tumors.
Key 2025–2026 milestones
- Thyroid eye disease: The first prescription in China after teprotumumab was included in the national reimbursement system was reported on January 1, 2026.
- Clinical alliance: A China thyroid eye disease diagnosis and treatment alliance was established in September 2025.
- Orbital surgery robotics: A national key research and development project on orbital surgical robotics started in April 2025.
Thyroid eye disease is an immune-mediated condition that can cause eyelid retraction, swelling, double vision, pain, exposure injury, and in severe cases, optic-nerve compression and vision loss. Treatment may involve control of thyroid disease, smoking cessation, lubricating care, glucocorticoids or other immune therapy, targeted treatment, orbital decompression, strabismus surgery, or eyelid surgery.
Teprotumumab is not appropriate for every patient. Eligibility may depend on disease activity, severity, optic-nerve status, hearing, blood glucose, pregnancy status, and previous treatment. Reimbursement inclusion can improve access, but patients still need specialist assessment and monitoring.
Orbital surgical robotics is an early technology-development direction. The potential value is precision in a confined anatomical space, but the platform must be evaluated for navigation accuracy, safety, surgeon control, training, and clinical outcomes. A research project does not automatically mean that robotic orbital surgery is routine clinical care.
Clinical profile: An orbital disease program combining targeted medical therapy, national multidisciplinary coordination, and next-generation surgical robotics.
4. How to Interpret These Innovations
The three Ninth People's Hospital programs address different but connected needs:
- Vascular malformations: targeted medicine combined with staged craniofacial treatment.
- Pathological scars: standardized adjuvant radiotherapy, molecular research, and personalized devices.
- Orbital disease: targeted treatment, reimbursement access, multidisciplinary care, and robotic surgery research.
Patients should distinguish between a clinical trial, a treatment approved for a specific indication, a professional consensus, a preclinical study, a medical-device registration, and a national research project. Each represents a different level of evidence and patient access.
5. How CMCS Helps International Patients Communicate with Specialists
For an international patient seeking vascular-malformation, craniofacial, scar, orbital, or thyroid-eye care in Shanghai, the first step is to match the clinical question with the right specialist team. China Medical Concierge Shanghai (CMCS) is a health management and medical coordination service that helps patients connect with specialist doctors and hospital resources in Shanghai. CMCS is not a hospital and does not independently diagnose or prescribe treatment.
Before a consultation, CMCS can help organize MRI, CT, ultrasound, angiography, ophthalmic examinations, pathology, photographs, previous operations, medication history, radiotherapy records, thyroid tests, hearing tests, and current symptoms. For overseas patients, these records can be arranged into a concise English medical summary for the specialist.
CMCS can help patients prepare focused questions such as:
- What is the exact vascular-malformation or scar subtype, and what imaging or pathology confirms it?
- Is the proposed targeted medicine approved for this diagnosis, or is it available only through a clinical trial?
- For a keloid, would surgery, radiotherapy, injections, silicone, pressure therapy, or a combination be most appropriate?
- For thyroid eye disease, is the disease active, sight-threatening, or stable, and what monitoring is required?
- Does the patient meet the criteria for reimbursement or a specialized treatment pathway?
- Is an orbital robotic procedure clinically available, or is it still a research project?
- What are the expected benefits, major risks, recurrence risks, costs, and follow-up requirements?
During the consultation, CMCS can assist with appointment coordination, medical interpretation, communication between the patient and the care team, and clarification of the doctor's recommendations. Afterward, a case manager can help organize the proposed next steps, identify additional tests or records, clarify the follow-up schedule, and coordinate further communication with the hospital.
The final treatment decision must be made by the patient and the treating medical team. CMCS does not independently select a drug, operation, device, radiotherapy plan, or clinical trial. Its role is to help the patient bring complete information to the right specialist and ensure that evidence, eligibility, risks, alternatives, access, and monitoring are discussed clearly.
To learn more about specialist consultations and treatment coordination in Shanghai, contact CMCS:
Email: contract@medicalsh.com
WhatsApp: Contact CMCS on WhatsApp
Website: medicalsh.com
Conclusion
The Ninth People's Hospital programs reviewed here show how craniofacial and orbital medicine is moving toward integrated care: targeted treatment for vascular malformations, staged cleft and reconstructive surgery, standardized keloid radiotherapy, molecular scar research, personalized devices, and multidisciplinary thyroid eye disease management.
For patients, the goal is not to pursue every new drug or device, but to identify the option that fits the diagnosis, disease activity, anatomy, age, previous treatment, and personal goals. This article was prepared from the team and program information provided for editorial use. Research findings, product names, approval status, clinical claims, and treatment access should be confirmed through the hospital, research team, regulatory authorities, and formally published studies. This article is for medical education only and is not individualized medical advice.
댓글 0개